Accelerate Diagnostics Q1 2024 GAAP EPS $(0.88) Misses $(0.72) Estimate, Sales $2.921M Miss $3.000M Estimate
Accelerate Diagnostics Q1 2024 GAAP EPS $(0.88) Misses $(0.72) Estimate, Sales $2.921M Miss $3.000M Estimate
加速診斷2024年第一季度GAAP每股收益（0.88）未達到預期（0.72）美元，銷售額292.1萬美元未達到3000萬美元的預期
Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.72) by 22.22 percent. This is a 48.54 percent increase over losses of $(1.71) per share from the same period last year. The company reported quarterly sales of $2.921 million which missed the analyst consensus estimate of $3.000 million by 2.63 percent. This is a 3.88 percent increase over sales of $2.812 million the same period last year.
Accelerate Diagnostics（納斯達克股票代碼：AXDX）公佈的季度虧損爲每股0.88美元，比分析師普遍預期的0.72美元（0.72美元）低22.22％。這比去年同期每股虧損1.71美元（1.71美元）增長了48.54％。該公司公佈的季度銷售額爲292.1萬美元，比分析師普遍預期的3000萬美元低2.63％。這比去年同期的281.2萬美元銷售額增長了3.88％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。